BioSpace News Archive

Turnstone Biologics Corp. announced with sadness that P. Joseph Campisi, Jr., Esq, the Company’s Chief Legal Officer, passed away on February 1, 2024, following a prolonged battle with cancer.

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that it will host a live webcast at 5 a.m. PT / 8 a.m. ET on Tuesday, February 27, 2024 to report its fourth quarter and full year 2023 financial results and provide a corporate update.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

On February 19, 2024, the Journal of American Medical Association•Neurology published online the key findings of a phase III clinical study investigating Sanbexin® sublingual tablets for the treatment of acute ischemic stroke.

Arcturus Therapeutics Holdings Inc. today announced that it will release its financial results for the quarter and year ended December 31, 2023 after the market close on Thursday, March 7.

Better Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its novel Cognitive Behavioral Therapy (CBT) platform intended to treat adults with metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH.

Eli Lilly and Company (NYSE: LLY) will participate in Cowen’s 44th Annual Health Care Conference on March 6, 2024.

Olatec Therapeutics, Inc. (Olatec), a leader in the developing class of selective NLRP3 inhibitors, today announced that Cure Parkinson’s granted an award to initiate a Phase 2 clinical trial investigating the potential of oral dapansutrile to slow or stop the progression of Parkinson’s disease.

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the fourth quarter and full-year 2023 before U.S. markets open on Tuesday, March 5, 2024.

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that three posters from the Company’s development pipeline will be presented at the American Academy of Neurology (AAN) 2024 Annual Meeting taking place April 13-18, 2024, in Denver, Colorado, USA.